Navigation Links
Logical Therapeutics to Present Data on LT-NS001 at American College of Gastroenterology Annual Meeting
Date:10/20/2009

WALTHAM, Mass., Oct. 20 /PRNewswire-USNewswire/ -- Logical Therapeutics, Inc. (Logical), a biopharmaceutical company focused on developing products that treat medical conditions associated with inflammation, has been selected to present the results of its clinical study comparing the gastrointestinal (GI) safety of its lead product LT-NS001, vs. naproxen at the American College of Gastroenterology's (ACG) Annual Scientific Meeting on October 27, 2009.

LT-NS001 is the first in a new class of bio-activated pro-drugs. It is a novel, patented new chemical entity (NCE) pro-drug of the popular non-steroidal anti-inflammatory drug (NSAID) naproxen, which is being developed by Logical Therapeutics to significantly reduce the gastrointestinal (GI) safety risks, including the formation of ulcers, associated with naproxen.

"We are very encouraged by the results of the LT-NS001 vs. naproxen study, and we look forward to sharing them later this month at the ACG meeting," said Peter A. Lankau, chief executive officer of Logical Therapeutics. "This novel, bio-activated pro-drug is being developed to fulfill an unmet need in the marketplace - to provide a single agent capable of delivering relief to those who suffer from chronic inflammatory conditions like arthritis, while significantly improving the GI safety and tolerability as compared to naproxen."

LT-NS001 Well-Tolerated with No Serious Adverse Events

LT-NS001 is unique among NSAIDs as it is pharmacologically inactive as a Cox inhibitor in the GI tract, but once absorbed into the bloodstream, it is converted rapidly and quantitatively to naproxen. In previous clinical studies, LT-NS001 was well-tolerated with no serious adverse events. In pre-clinical testing, LT-NS001 demonstrated significantly less damage to the gastrointestinal tract than equivalent doses of naproxen. Naproxen is widely regarded as the NSAID with the most favorable cardiovascular safety prof
'/>"/>

SOURCE Logical Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Article Published in Expert Opinion on Biological Therapy Evaluates StemEx(R) (carlecortemcel-l) for Leukemia and Lymphoma
2. Interim Phase II Data Presented at XIV World Congress of Neurological Surgery Supports Potential of Peregrines Cotara(R) for Treatment of Brain Cancer
3. Cytel Signs Cooperative Research And Development Agreement With FDA Center for Devices and Radiological Health (CDRH)
4. Clinical and Histopathological Results Using Pollogens TriPollar(TM) Radio Frequency Technology Published in the June Issue of the Journal of Cosmetic and Laser Therapy
5. Neurobiological Technologies Partner, Celtic Pharma, Announces Results of XERECEPT(R) Phase 3 Clinical Program
6. Logical Therapeutics Appoints Peter A. Lankau as CEO and Director
7. Neurobiological Technologies Reports Receipt of $1.5 Million Royalty Payment for Quarterly Sales of Memantine
8. Genetic Research Leads to New Discovery in Understanding Rare Neurological Disorder
9. Study Shows How Defective DNA Repair Triggers Two Neurological Diseases
10. Neurobiological Technologies Announces Viprinex(TM) Does Not Pass Interim Futility Analysis
11. The Government of Canada Procures IMVAMUNE(R) Smallpox Vaccine for the Countrys Biological Preparedness

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)... , , LYON, France, Nov. 19 ...tes supplying dangerous and illegal medicines, Ope...dinated by INTERPOL and the World Health Organizat...eiting Taskforce (IMPACT) to highlight the dangers...lobal initiative resulted in a series of arrests a...
(Date:11/19/2009)... , , ABBOTT PARK, Ill., Nov. 19 /PRNewswi... Abbott (NYSE: ABT ) as one of its Most Admired ...ar. The Deal honored Abbott as its Most Admired...e strategic use of acquisitions and divestitures s...ott has reshaped its business portfolio with a foc...
(Date:11/19/2009)... , , NEWPORT NEWS, Va., Nov. 19 /PRNewswir...st Imaging (BSGI/MBI) has been recognized and endo...fight against breast cancer: The Society of Breast...s. Both societies published articles supporting th... technology for the early detection of breast canc...
Breaking Medicine Technology:International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 2The Deal Names Abbott Top Dealmaker for Second Consecutive Year 3Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 2Esteemed Endorsements Recognize Promising Future of Breast-Specific Gamma Imaging (BSGI) 3EPIX Pharmaceuticals Inc Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered F 55886 1EPIX Pharmaceuticals Inc Announces the P2Y2 Gastrointestinal Early Development Candidate Program Will Be Part of the Intellectual Property Offered F 55886 2Environmental Tectonics Corporations BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 13775 1Environmental Tectonics Corporations BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 13775 2Environmental Tectonics Corporations BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 13775 3Environmental Tectonics Corporations BioMedical Systems Division Announces the Sale of a Monoplace Hyperbaric Chamber 13775 4GHX Working with Hospitals and Suppliers to Enable Use of Industry Standard Location and Organization Identifiers in Transactions and Compliance with 55880 1GHX Working with Hospitals and Suppliers to Enable Use of Industry Standard Location and Organization Identifiers in Transactions and Compliance with 55880 2GHX Working with Hospitals and Suppliers to Enable Use of Industry Standard Location and Organization Identifiers in Transactions and Compliance with 55880 3GHX Working with Hospitals and Suppliers to Enable Use of Industry Standard Location and Organization Identifiers in Transactions and Compliance with 55880 4
(Date:11/21/2009)... HAPPYneuron,s most popular and addictive g...d iPod Touch. , Mountain ...s most popular and addictive game, SplitWords, is ...Words is designed to help banish that ,tip of the ...one brain game challenges the brain by encouragin...
(Date:11/20/2009)...TON, NJ, Nov. 20 /PRNewswire-FirstCall/ - NUCRYST ...al Meeting of Shareholders will be held on Monday,...to consider approval of two special resolutions. T...orize the sale of all or substantially all of the ...ided for in the asset purchase agreement dated Nov...
(Date:11/20/2009)...SON, N.J., Nov. 20 Rates... have peaked in late October, but the pandemic flu...ss in all age groups, including the elderly, accor...ated (NYSE: DGX ), the world,s leading provider ...,, In its most recent Quest Diagnostics Health ...
(Date:11/20/2009)...S, Nov. 20 The followin...tor of the Nevada Health Care Association: ,, "... and thanks Senate Majority Leader Harry Reid for ...toward our goal of protecting every Nevada seniors... preserving the strength and viability of our stat...
(Date:11/20/2009)...gton) November 20, 2009Emergency medical service (...mated 350,000 cardiac arrests each year. Only 5 t...est survive. Better quality cardiopulmonary resus...rs may be associated with better patient outcome. ...e largest clinical research network to study preho...
Breaking Medicine News(10 mins):Health News:HAPPYneuron releases iPhone Brain Game 2Health News:HAPPYneuron releases iPhone Brain Game 3Health News:NUCRYST Announces Special Meeting of Shareholders 2Health News:NUCRYST Announces Special Meeting of Shareholders 3Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 2Health News:Effect of real-time CPR feedback reported at resuscitation science symposium 3
...RNewswire-FirstCall/ - QLT Inc. (NASDAQ:QLTI;,TSX:...bal sales of QLT,s,Visudyne(R) (verteporfin) produ...ber 30, 2007. This represents a decrease of 35.1% ...proximately US$9.4,million, representing 19.3% of ...
... hard to think of scientists in laboratories worki...ice or other laboratory animals, but animals roles...n be minimal. , Researchers at the University of...ically discarded that mimics arthritic joints. Thi...
...night at Fair Election Commission Hearing After CM...itations, FRESNO, Calif., Oct. 17 Today, healthc...edical Centers are filing a series of,charges agai...with management to,discuss a Free and Fair Electio...
... The California Science,Center,s Science Matters s...cs of Fear" in a free program from 1 - 3:30 p.m. o...lists will discuss the current science of,fear, wh...es manipulated by the media. Speakers will also ad...
...ed to Accelerate Manufacture of Clinical Trial ...ON HILLS, Mich., Oct. 17 Regulatory Affairs,Assoc...nning FDA approval,for new drugs and medical devic...manufacture of drugs used in clinical,trials calle...
...National Football League,(NFL), National Hockey Le...,Association (NHLPA) have agreed to sponsor an edu...y the National Academy of Neuropsychology (NAN) an...,players, parents, physicians and coaches, and wil...
Other Medicine News:Health News:QLT announces Visudyne(R) sales for third quarter and provides Visudyne sales guidance for 2007 2Health News:QLT announces Visudyne(R) sales for third quarter and provides Visudyne sales guidance for 2007 3Health News:In vitro models will minimize animal use in arthritis studies 2Health News:Federal Charges Filed Against Community Medical Centers Management 2Health News:Regulatory Affairs Associates Gets New Drugs Tested Faster, Wins 2007 Innovation Michigan Award 2Health News:NFL, NHL and NHLPA Team Up in Sports Concussion Education Campaign 2
CROSSER™ 14 Coronary CTO Recanilazation System
...a 5X is a whole blood hematology control manufactu...20, and the Coulter AcT5diff instruments. The comp... differential, positioning the populations within ...The product offers 105-day closed-vial stability a...
...l-Chex is a spinal and body fluid control with dis...n the same manner as a patient sample, the white b...ntrol is assayed for manual cell counting, the fiv...he two-part polymorphonuclear and mononuclear diff...
Antelys Peek Lumbar Technologies
Medicine Products: